Technologies
Competitive Advantages:
A novel antibiofilm agent, Treats and prevents biofilm growth, Inhibits drug resistant bacterial infections including MRSA, Low toxicity towards mammalian cells.
Provided is a darwinolide compound having a previously undescribed carbon skeleton and the crystalline form thereof. Also provided are processes of isolating darwinolide, compositions comprising darwinolide, and methods of treating infection, such as a methicillin-resistant Staphylococcus aureus biofilm infection.USF researchers have developed a method of treating or preventing drug resistant bacterial infections including methicillin-resistant biofilm infections such as MRSA via the administration of a therapeutically effective amount of darwinolide. Darwinolide is a natural product with selective pharmacological properties toward the biofilm phase of MRSA. It has been shown that darwinolide reduces, eliminates or otherwise inhibits MRSA biofilms with a high degree of cytotoxicity towards MRSA. Preliminary results showed that after darwinolide treatment, only 1.6% of MRSA cells demonstrated growth. Further, this compound presents low toxicity towards mammalian cells and has a unique chemical structure with a previously undescribed carbon skeleton. Therefore, darwinolide and its variants have the potential to serve as effective treatments against resistant infectious diseases and may help in the development of a new generation of antibiofilm agents.
Competitive Advantages:
Modifies complex extracts from plants, Prepare pharmaceutical compositions, Applicable to other complex mixtures.
The present disclosure relates to methods of modifying complex extracts such that components or mixtures of components are selectively removed or added, thus providing a complex mixture that does not naturally occur with a refined or a tuned therapeutic or nutraceutical effect. In various aspects, the complex extract can be an extract obtained from one or more plants, e.g., an extract obtained from green tea leaves. The present disclosure pertains to compositions obtained by the disclosed methods, nutraceutical compositions comprising same, pharmaceutical compositions comprising same, and methods of treating various conditions, including physiological dysfunctions associated with elevated reactive oxygen species and/or inflammatory molecule, e.g., TNFa, expression using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Our researchers have developed a method of modifying complex extracts in which components or mixtures of components are selectively removed or added, thus providing a complex mixture that does not naturally occur. The method involves a selective deletion chromatography technique to prepare a composition which has a refined therapeutic effect. The complex extract can be an extract obtained from one or more plants, e.g., an extract obtained from green tea leaves. This method can be used to prepare nutraceutical compositions, pharmaceutical compositions, and compositions for treating various conditions, including physiological dysfunctions associated with elevated reactive oxygen species and/or inflammatory molecule.
Competitive Advantages:
Specific inhibition of Leishmania donovani parasites, A natural drug candidate, Does not produce toxic side effects.
In one aspect, methods and compositions for treating parasitic diseases, for example, leishmaniasis.USF researchers have identified a novel metabolite derived from an Antarctic marine coral that shows promise as a new treatment option for leishmaniasis infections. Antactic marine invertebrates are being investigated for their natual chemical protective mechanisms used against predators. This natural product chemistry is ideal for new drug development efforts. the identified metabolite has exhibited specific inhibition of Leishmania donovani parasites in laboratory settings.
Competitive Advantages:
A novel molecule that can inhibit P. falciparum in malaria, Bypasses drug resistance, Limited toxicity towards human cells.
Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liverstage parasite development of a protozoan parasite, such as Plasmodium falciparum.USF researchers have developed a novel modified hexapeptide called friomaramide. It inhibits the growth of P. falciparum to a similar degree as the antimalarial drug primaquine, with the added benefit of bypassing growing antimalarial resistance. It is also less toxic to human cells. Friomaramide may prove to be a huge benefit to the millions of people infected with malaria worldwide every year.
Described herein are Dendrilla membranosa compounds and derivatives thereof. Also described herein are formulations that can contain an amount of one or more Dendrilla membranosa compounds or derivatives thereof and a carrier. Also described herein are methods of administering one or more Dendrilla membranosa compound and/or derivative thereof or a formulation thereof to a subject in need thereof.Biofilms are formed by all bacterial species. In the context of human disease, biofilms are the driving force behind many chronic infections, including UTIs, upper respiratory infections and periodontitis. Biofilms also form on implanted devices, such as catheters, artificial joints, pacemakers, and pins/plates. Interventions strategies targeting multi?drug resistant biofilms would save numerous lives and significantly limit morbidity. Therefore, there is an urgent unmet need to develop molecules that can actively impact cell viability with biofilms. USF inventors have discovered that the Antarctic sponge Dendrilla membranosa produces natural diterpene metabolites, that can eradicate bacterial biofilms. They discovered that these metabolites and their derivatives are effective in eradicating the biofilms of Methicillin-resistant Staphyloccocus aureus (MRSA) and Actinetobacter baumannii. This bypasses one of the main factors in bacterial drug resistance. The antibiofilm terpenoids were also tested against mammalian cells, and showed no signs of mammalian cytotoxicity. These metabolites can be used to decrease resistance in bacterial infections while also keeping the human host safe from harm.
Advantages:
Exceptional precision in addressing inflammation, minimizing potential side effects.
Unique COX-2 interaction reduces the risk of adverse reactions.
Versatile effectiveness across various inflammatory disorders, providing relief to a wide range of patients.
The present disclosure is directed to methods for the treatment of inflammation or pain, particularly methods using compositions containing a compound of formula (I).This technology addresses a significant healthcare challenge related to the management of inflammation and its associated disorders, particularly pain. Inflammation, which represents a complex biological response, plays a pivotal role in various medical conditions, often leading to discomfort, pain, and occasionally irreversible tissue damage. This innovative approach revolves around the administration of a meticulously formulated composition containing a unique compound referred to as formula (I). The primary objective of this technological advancement is to tackle various forms of inflammation, encompassing both acute and chronic cases. It also extends its applicability to a wide range of inflammatory disorders, including but not limited to arthritis, gastrointestinal issues, and vascular diseases. At its core, formula (I) demonstrates noteworthy inhibitory activity against tumor necrosis factor-alpha (TNF-?), a pivotal mediator of inflammation. What sets this novel compound apart is its minimal to negligible inhibitory effect on cyclooxygenase-2 (COX-2), thereby distinguishing it from conventional anti-inflammatory drugs. This technological advancement holds the promise of enhancing precision in targeting inflammation, potentially mitigating the associated side effects linked to COX-2 inhibition. Consequently, it emerges as a potential safer and more efficacious solution for individuals in need. The compound's selectivity and potency in modulating inflammation pathways hold substantial potential for future pharmaceutical development, thereby offering new prospects for personalized anti-inflammatory therapies.